Martin N Pruschy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3891807/publications.pdf

Version: 2024-02-01

95 3,768 31 59
papers citations h-index g-index

99 99 5555
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation. Radiation Oncology, 2022, 17, 72.	1.2	2
2	Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model. Neoplasia, 2022, 31, 100812.	2.3	6
3	Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance. Molecular Cancer Research, 2021, 19, 1051-1062.	1.5	3
4	Combined Radiochemotherapy: Metalloproteinases Revisited. Frontiers in Oncology, 2021, 11, 676583.	1.3	7
5	Systematic Review on the Association of Radiomics with Tumor Biological Endpoints. Cancers, 2021, 13, 3015.	1.7	11
6	Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells. Frontiers in Oncology, 2021, 11, 664462.	1.3	2
7	Interfering with Tumor Hypoxia for Radiotherapy Optimization. Journal of Experimental and Clinical Cancer Research, 2021, 40, 197.	3 . 5	70
8	Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1222-1233.	0.4	11
9	The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy. Cancer Research Communications, 2021, 1, 164-177.	0.7	7
10	The relative biological effectiveness of proton irradiation in dependence of DNA damage repair. British Journal of Radiology, 2020, 93, 20190494.	1.0	10
11	Evaluation of 18Fâ€FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. Head and Neck, 2020, 42, 163-170.	0.9	7
12	Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiotherapy and Oncology, 2020, 150, 62-69.	0.3	3
13	Proton Irradiation Increases the Necessity for Homologous Recombination Repair Along with the Indispensability of Non-Homologous End Joining. Cells, 2020, 9, 889.	1.8	35
14	Probing spatiotemporal fractionation on the preclinical level. Physics in Medicine and Biology, 2020, 65, 22NT02.	1.6	3
15	Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma. Acta Oncológica, 2019, 58, 1514-1518.	0.8	10
16	PO-1070 Identification of biologically active factors in ionizing radiation regulated secretome. Radiotherapy and Oncology, 2019, 133, S595.	0.3	0
17	OC-0054 Tumor reoxygenation and image-guided SBRT for the treatment of murine colorectal liver metastases. Radiotherapy and Oncology, 2019, 133, S20.	0.3	O
18	Overview of research and therapy facilities for radiobiological experimental work in particle therapy. Report from the European Particle Therapy Network radiobiology group. Radiotherapy and Oncology, 2018, 128, 14-18.	0.3	21

#	Article	lF	Citations
19	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clinical Cancer Research, 2018, 24, 882-895.	3.2	73
20	Targeting Tumor Microenvironment and Metabolism to Overcome Radiation Resistance. Progress in Tumor Research, 2018, , 25-40.	0.1	0
21	PO-1056: Decipering the mechanism of ADAM17- mediated radioresistance in NSCLC. Radiotherapy and Oncology, 2018, 127, S592-S593.	0.3	1
22	Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice. Clinical Cancer Research, 2018, 24, 3981-3993.	3.2	50
23	MAP4K4 controlled integrin \hat{l}^21 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. Oncotarget, 2018, 9, 23220-23236.	0.8	32
24	Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies. International Journal of Particle Therapy, 2018, 5, 133-139.	0.9	1
25	SP-0480: Secretome as novel target for lung cancer. Radiotherapy and Oncology, 2017, 123, S254.	0.3	0
26	The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy and Oncology, 2017, 124, 433-438.	0.3	11
27	Post-radiochemotherapy PET radiomics in head and neck cancer – The influence of radiomics implementation on the reproducibility of local control tumor models. Radiotherapy and Oncology, 2017, 125, 385-391.	0.3	89
28	Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. Child's Nervous System, 2017, 33, 1463-1471.	0.6	7
29	The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. Oncotarget, 2017, 8, 23702-23712.	0.8	28
30	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. Oncotarget, 2017, 8, 87124-87135.	0.8	8
31	Hypoxia-Related Marker GLUT-1, CAIX, Proliferative Index and Microvessel Density in Canine Oral Malignant Neoplasia. PLoS ONE, 2016, 11, e0149993.	1.1	9
32	Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4428-4439.	3.2	39
33	Combined Treatment Strategies for Microtubule Stabilizing Agent-Resistant Tumors. Journal of the National Cancer Institute, 2015, 107, .	3.0	17
34	Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. Immunity, 2015, 42, 767-777.	6.6	135
35	High dose rate and flattening filter free irradiation can be safely implemented in clinical practice. International Journal of Radiation Biology, 2015, 91, 778-785.	1.0	12
36	Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation. Radiotherapy and Oncology, 2015, 116, 374-380.	0.3	92

3

#	Article	IF	Citations
37	Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDG uptake in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2015, 117, 125-131.	0.3	18
38	Abstract C145: Targeted radiosensitization of non-small cell lung cancer (NSCLC) through ADAM17 inhibition. , 2015, , .		0
39	Abstract A185: Combined treatment strategies for microtubule interfering agent-resistant tumors. , 2015, , .		O
40	Abstract A163: The combined treatment modality of a hypoxia-activated prodrug (Evofosfamide) with ionizing radiation. , 2015, , .		0
41	Deficiency in Homologous Recombination Renders Mammalian Cells More Sensitive to Proton Versus Photon Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 175-181.	0.4	95
42	Ionizing radiation induces tumor cell lysyl oxidase secretion. BMC Cancer, 2014, 14, 532.	1.1	31
43	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 159-166.	0.4	29
44	The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion. Radiation Oncology, 2013, 8, 105.	1.2	10
45	Impaired long-term memory retention: Common denominator for acutely or genetically reduced hippocampal neurogenesis in adult mice. Behavioural Brain Research, 2013, 252, 275-286.	1.2	38
46	Microtubule stabilising agents and ionising radiation: Multiple exploitable mechanisms for combined treatment. European Journal of Cancer, 2013, 49, 245-253.	1.3	18
47	Abstract B1: Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation, 2013, , .		16
48	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. Oncology, 2012, 83, 1-9.	0.9	41
49	Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. Journal of Immunology, 2012, 189, 558-566.	0.4	363
50	Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer, 2012, 12, 571.	1.1	104
51	Dynamics of Tumor Hypoxia in Response to Patupilone and Ionizing Radiation. PLoS ONE, 2012, 7, e51476.	1.1	13
52	Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer, 2011, 71, 370-371.	0.9	4
53	Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer, 2011, 73, 294-301.	0.9	10
54	Metabolism of tumors under treatment: Mapping of metabolites with quantitative bioluminescence. Radiotherapy and Oncology, 2011, 99, 398-403.	0.3	11

#	Article	IF	Citations
55	Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 2011, 30, 2823-2835.	2.6	27
56	c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer, 2011, 11, 74.	1.1	22
57	MVP and vaults: a role in the radiation response. Radiation Oncology, 2011, 6, 148.	1.2	33
58	lonizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study. Radiation Oncology, 2011, 6, 66.	1.2	6
59	The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro-Oncology, 2011, 13, 1000-1010.	0.6	32
60	Abstract 1347: BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity. Cancer Research, 2011, 71, 1347-1347.	0.4	6
61	Substrate screening identifies a novel target sequence for the proteasomal activity regulated by ionizing radiation. Proteomics, 2010, 10, 304-314.	1.3	1
62	Role of the Microenvironment for Radiosensitization by Patupilone. Clinical Cancer Research, 2009, 15, 1335-1342.	3.2	15
63	RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer, 2009, 9, 10.	1.1	38
64	Differential DNA Repair Mechanisms in Response to Proton and Photon Irradiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, S19-S20.	0.4	0
65	Role of the Microenvironment and Tumor Hypoxia for Radiosensitization by Patupilone. International Journal of Radiation Oncology Biology Physics, 2009, 75, S94-S95.	0.4	1
66	Abstract C233: BAL27862: A unique microtubuleâ€targeted agent with a potential for the treatment of human brain tumors. , 2009, , .		2
67	Temperature sensitivity of phospho-Ser473-PKB/AKT. Biochemical and Biophysical Research Communications, 2008, 375, 399-404.	1.0	20
68	Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation. American Journal of Pathology, 2008, 173, 1173-1185.	1.9	113
69	Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents. Current Pharmaceutical Design, 2007, 13, 519-535.	0.9	25
70	Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Molecular Cancer Therapeutics, 2007, 6, 2496-2504.	1.9	20
71	HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. Gene Therapy, 2007, 14, 1143-1151.	2.3	22
72	Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer, 2007, 7, 143.	1.1	17

#	Article	IF	Citations
73	lonizing Radiation Antagonizes Tumor Hypoxia Induced by Antiangiogenic Treatment. Clinical Cancer Research, 2006, 12, 3518-3524.	3.2	54
74	G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1390-1398.	0.4	12
75	Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo. Clinical Cancer Research, 2005, $11,1588-1596$.	3.2	42
76	Differential Activation of the Phosphatidylinositol 3′-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells. Cancer Research, 2004, 64, 5398-5406.	0.4	55
77	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene, 2004, 23, 4624-4635.	2.6	70
78	Profiling treatment-specific post-translational modifications in a complex proteome with subtractive substrate phage display. Proteomics, 2004, 4, 2796-2804.	1.3	7
79	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 361-368.	0.4	12
80	Apoptosis-modulating agents in combination with radiotherapyâ€"current status and outlook. International Journal of Radiation Oncology Biology Physics, 2004, 58, 542-554.	0.4	123
81	Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. British Journal of Cancer, 2003, 88, 1785-1792.	2.9	53
82	p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Annals of the Rheumatic Diseases, 2003, 62, 1139-1144.	0.5	35
83	Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases. International Journal of Radiation Oncology Biology Physics, 2001, 49, 561-567.	0.4	40
84	Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth. British Journal of Cancer, 2001, 85, 2010-2016.	2.9	153
85	Overexpression of Bcl-2 enhances sensitivity of L929 cells to a lipophilic cationic photosensitiser. Cell Death and Differentiation, 2001, 8, 204-206.	5.0	6
86	Glucose and Palmitic Acid Induce Degeneration of Myofibrils and Modulate Apoptosis in Rat Adult Cardiomyocytes. Diabetes, 2001, 50, 2105-2113.	0.3	180
87	Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells. British Journal of Cancer, 1999, 80, 693-698.	2.9	25
88	Ceramide Induces Cytochrome c Release from Isolated Mitochondria. Journal of Biological Chemistry, 1999, 274, 6080-6084.	1.6	240
89	Molecular mechanisms of radioresistance: Applications for head and neck cancer. Zeitschrift Fur Medizinische Physik, 1998, 8, 119-123.	0.6	1
90	The Proto-oncogene c-fos Mediates Apoptosis in Murine T-Lymphocytes Induced by Ionizing Radiation and Dexamethasone. Biochemical and Biophysical Research Communications, 1997, 241, 519-524.	1.0	22

#	Article	IF	CITATIONS
91	Lateral clustering of the adhesive ectodomain: a fundamental determinant of cadherin function. Current Biology, 1997, 7, 308-315.	1.8	333
92	Recombinant Human Renin Produced in Different Expression Systems: Biochemical Properties and 3D Structure. Protein Expression and Purification, 1996, 7, 81-91.	0.6	22
93	Facilitated nuclear transport of calmodulin in tissue culture cells Journal of Cell Biology, 1994, 127, 1527-1536.	2.3	67
94	Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. Chemistry and Biology, 1994, 1, 163-172.	6.2	61
95	Primary structure of the cAMP-dependent phosphorylation site of the plasma membrane calcium pump. Biochemistry, 1989, 28, 4253-4258.	1.2	142